​​​
  1. Retain ‘neutral’ on Cipla, target price Rs 600: Motilal Oswal

Retain ‘neutral’ on Cipla, target price Rs 600: Motilal Oswal

Cipla’s 3Q revenues came in at Rs 31 billion (up 12% y-o-y) and were 9% below our estimates primarily due to flat domestic sales, partially offset by strong performance in South Africa and other EMs.

By: | Mumbai | Updated: February 12, 2016 2:23 AM
Cipla stake

Domestic formulations sales were flat in 3Q due to change in distribution policy. Excluding impact of distribution policy changes, domestic business grew at 11% y-o-y. Management expects this to normalize in coming quarters. (Reuters photo)

Cipla’s 3Q revenues came in at `31 billion (up 12% y-o-y) and were 9% below our estimates primarily due to flat domestic sales, partially offset by strong performance in South Africa and other EMs. EBITDA at Rs 4.5 billion (18% y-o-y decline) was 35% below estimates due to poor business mix, one-offs and high R&D cost. PAT at ` 3.4 billion (5% growth) was below our estimates due to weak sales and margins, partially offset by lower tax rate (3% of PBT).

Domestic formulations sales were flat in 3Q due to change in distribution policy. Excluding impact of distribution policy changes, domestic business grew at 11% y-o-y. Management expects this to normalize in coming quarters.

EBITDA margin at 14.6% (decline of >500bp y-o-y)–significantly below our estimates due to change in business mix, higher distribution cost (250bp) in India, higher R&D cost in 3Q (up 200bp y-o-y) and ZAR depreciation (70bp). Going ahead, margin improvement due to ramp-up of respiratory business and strong US business growth will get partially offset by negative operating leverage in recently opened front-ends.

We maintain Neutral rating on the stock with TP of Rs 600 @ 18x FY18E PER (vs Rs710 @ 20x). We have cut our FY17/ 18E EPS by 3-4% as e build in slower margin improvement.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top